: Here, we present the case of a 47-year-old woman diagnosed with luminal B breast cancer subtype and provide an in-depth analysis of her gene mutations, chromosomal alterations, mRNA and protein expression changes. We found a point mutation in the FGFR2 gene, which is potentially hyper-activating the receptor function, along with over-expression of its ligand FGF20 due to genomic amplification. The patient also harbors somatic and germline mutations in some mismatch repair (MMR) genes, with a strong MMR mutational signature. The patient displays high microsatellite instability (MSI) and tumor mutational burden (TMB) status and increased levels of CTLA-4 and PD-1 expression. Altogether, these data strongly implicate that aberrant FGFR signaling, and defective MMR system might be involved in the development of this breast tumor. In addition, high MSI and TMB in the context of CTLA-4 and PD-L1 positivity, suggest the potential benefit of immune checkpoint inhibitors. Accurate characterization of molecular subtypes, based on gene mutational and expression profiling analyses, will be certainly helpful for individualized treatment and targeted therapy of breast cancer patients, especially for those subtypes with adverse outcome.

Yang, X., Smirnov, A., Buonomo, O.c., Sica, G., Mauriello, A., Shi, Y., et al. (2023). A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency. CELL DEATH DISCOVERY, 9, 1-8 [10.1038/s41420-023-01650-4].

A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency

Smirnov, Artem;Buonomo, Oreste Claudio;Sica, G;Mauriello, Alessandro;Candi, Eleonora;Bernassola, Francesca
2023-10-02

Abstract

: Here, we present the case of a 47-year-old woman diagnosed with luminal B breast cancer subtype and provide an in-depth analysis of her gene mutations, chromosomal alterations, mRNA and protein expression changes. We found a point mutation in the FGFR2 gene, which is potentially hyper-activating the receptor function, along with over-expression of its ligand FGF20 due to genomic amplification. The patient also harbors somatic and germline mutations in some mismatch repair (MMR) genes, with a strong MMR mutational signature. The patient displays high microsatellite instability (MSI) and tumor mutational burden (TMB) status and increased levels of CTLA-4 and PD-1 expression. Altogether, these data strongly implicate that aberrant FGFR signaling, and defective MMR system might be involved in the development of this breast tumor. In addition, high MSI and TMB in the context of CTLA-4 and PD-L1 positivity, suggest the potential benefit of immune checkpoint inhibitors. Accurate characterization of molecular subtypes, based on gene mutational and expression profiling analyses, will be certainly helpful for individualized treatment and targeted therapy of breast cancer patients, especially for those subtypes with adverse outcome.
2-ott-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/18
English
Yang, X., Smirnov, A., Buonomo, O.c., Sica, G., Mauriello, A., Shi, Y., et al. (2023). A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency. CELL DEATH DISCOVERY, 9, 1-8 [10.1038/s41420-023-01650-4].
Yang, X; Smirnov, A; Buonomo, Oc; Sica, G; Mauriello, A; Shi, Y; Bischof, J; Woodsmith, J; Melino, G; Candi, E; Bernassola, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
A_primary_luminalHER2_negative.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.41 MB
Formato Adobe PDF
2.41 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/341185
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact